ERYTECH Announces Third DSMB Safety Review and Continuation of Its Phase 2b Study in Acute Myeloid Leukemia

ERYTECH announces that an independent Data and Safety Monitoring Board (DSMB1) completed its third safety assessment of the company’s Phase 2b ENFORCE 1 study in acute myeloid leukemia (AML) and that enrollment will continue until completion.

Menu